Apogee Therapeutics (APGE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.08
- Estimate
- -$0.96
- Surprise
- -12.4%
- Score today
- 4.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Apogee Therapeutics (APGE) reported a wider loss than forecast — diluted EPS of -$1.08 against the -$0.96 estimate (a 12.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates APGE Sell at 4.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -12.4% surprise compares with a -0.5% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Pipeline: zumilokibart (APG777)
- Target reached (-13.3% upside)
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $135.11
- Price target
- $155.33
- Stop
- $134.85
- Upside to target
- +15.0%
Risk check: RSI 96 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 3.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
APGE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $10.22B
- P/E (fwd)
- -26.0
- 52-week range
- $35.39–$135.09
- Off 52-week high
- -0.0%
- RSI (14)
- 96
- Volume vs avg
- 3.69×
- Score today
- 4.3/10